These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 36272527)

  • 1. Alternative Transplantation With Post-Transplantation Cyclophosphamide in Aplastic Anemia: A Retrospective Report From the BMF-WG of Hunan Province, China.
    Gong S; Chen C; Chen K; Yang R; Wang L; Yang K; Hu J; Nie L; Su T; Xu Y; He X; Yang L; Xiao H; Fu B
    Transplant Cell Ther; 2023 Jan; 29(1):48.e1-48.e7. PubMed ID: 36272527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia.
    Arcuri LJ; Nabhan SK; Cunha R; Nichele S; Ribeiro AAF; Fernandes JF; Daudt LE; Rodrigues ALM; Arrais-Rodrigues C; Seber A; Atta EH; de Oliveira JSR; Funke VAM; Loth G; Junior LGD; Paz A; Calixto RF; Gomes AA; Araujo CES; Colturato V; Simoes BP; Hamerschlak N; Flowers ME; Pasquini R; Rocha V; Bonfim C
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2311-2317. PubMed ID: 32949751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Conditioning Regimen and Graft-versus-Host Disease Prophylaxis on The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation for High-Risk Severe Aplastic Anemia in Children and Young Adults: A Report from the Pediatric Severe Aplastic Anemia Consortium of India.
    Kharya G; Jaiswal SR; Bhat S; Raj R; Yadav SP; Dua V; Sen S; Bakane A; Badiger S; Uppuluri R; Rastogi N; Sachdev M; Sharma B; Saifullah A; Chakrabarti S
    Transplant Cell Ther; 2023 Mar; 29(3):199.e1-199.e10. PubMed ID: 36572385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.
    DeZern AE; Zahurak M; Symons H; Cooke K; Jones RJ; Brodsky RA
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):498-504. PubMed ID: 28013015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation.
    Arslan S; Desai A; Yang D; Mokhtari S; Tiemann K; Otoukesh S; Samara Y; Blackmon A; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Aribi A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
    Transplant Cell Ther; 2024 Oct; 30(10):1013.e1-1013.e12. PubMed ID: 39122188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
    Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
    Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
    Soltermann Y; Heim D; Medinger M; Baldomero H; Halter JP; Gerull S; Arranto C; Passweg JR; Kleber M
    Ann Hematol; 2019 Jun; 98(6):1485-1493. PubMed ID: 30915500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of Modified Post-Transplantation Cyclophosphamide and Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin Regimens for Haploidentical Stem Cell Transplantation in Patients with Aplastic Anemia.
    Li Y; Lu X; Wang N; Zhang X; Cao Y; Xiao Y; Meng F; Zhang D; You Y; Zou L; Cheng H; Guo J; Zhang Y; Huang Z; Yuan G; Wei J; Wang H; Xia L; Zhang Y
    Transplant Cell Ther; 2022 Jul; 28(7):396.e1-396.e9. PubMed ID: 35513253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Study of a Modified Post-Transplantation Cyclophosphamide Regimen for Severe Aplastic Anemia Patients with HLA-Haploidentical Transplantation.
    Wu L; Zhou M; Li Y; Chen X; Mo W; Wang C; Xu S; Zhou W; Deng T; Zhou R; Pan S; Wang S; Zhang Y
    Transplant Cell Ther; 2023 Jul; 29(7):463.e1-463.e7. PubMed ID: 37098408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients.
    Ma X; Xu Z; Han T; Zhang Y; Han W; Fu H; Zhang X; Lin F; Huang X; Xu L
    Front Immunol; 2023; 14():1173320. PubMed ID: 37234156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.
    Zhang L; Li J; Liang W; Zhang X; Chen S; Shi Y; Hao M; Zhao X; Gong M; Wei J; He Y; Jiang E; Han M; Zhang F; Feng S
    Front Immunol; 2024; 15():1425076. PubMed ID: 39221245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia.
    Onishi Y; Mori T; Yamazaki H; Hiramoto N; Zaimoku Y; Kanaya M; Matsue K; Onizuka M; Aotsuka N; Uchida N; Onodera K; Kanda J; Nakamae H; Yamamoto R; Kuriyama T; Kimura T; Ichinohe T; Atsuta Y;
    Transplant Cell Ther; 2023 Dec; 29(12):766.e1-766.e8. PubMed ID: 37730121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploidentical Peripheral Stem Cell Transplantation for Young Patients with Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide and Methotrexate.
    Yang K; Gong S; Jiang T; Liang X; Hu J; Zhu P; Nie L; Xu Y; Fu B;
    Transplant Cell Ther; 2021 May; 27(5):429.e1-429.e7. PubMed ID: 33965186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
    Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.
    Wang Y; Wu DP; Liu QF; Xu LP; Liu KY; Zhang XH; Yu WJ; Xu Y; Huang F; Huang XJ
    J Hematol Oncol; 2019 Sep; 12(1):88. PubMed ID: 31481121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.
    Bacigalupo A; Socie' G; Lanino E; Prete A; Locatelli F; Locasciulli A; Cesaro S; Shimoni A; Marsh J; Brune M; Van Lint MT; Oneto R; Passweg J;
    Haematologica; 2010 Jun; 95(6):976-82. PubMed ID: 20494932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
    Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
    Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.